EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment adherence, persistence, and effectiveness of fixed dose combination versus free combination therapy of rosuvastatin–ezetimibe as a lipid-lowering therapy

Mihail Samnaliev, Irfan Khan, Praveen Potukuchi, Kelly Lee, Genevieve Garon, Charlie Nicholls

Frontiers in Cardiovascular Medicine · 16.05.2025 · 12

DOI: 10.3389/fcvm.2025.1461416 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 16.05.2025. Verfasst von Mihail Samnaliev und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of RWE and HEOR Practice, Axtria, Boston, MA, United States. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Guidelines for dyslipidemia management recommend adding ezetimibe for patients with dyslipidemia inadequately controlled with statin monotherapy. A fixed-dose combination (FDC) of statin and ezetimibe may improve persistence and adherence and hence reduce LDL-C further compared to free-combination treatment (FCT). The primary aim was to compare persistence/adherence with FDC versus FCT of rosuvastatin and ezetimibe (R/E); the secondary aim was to assess the impact of treatment adherence and persistence to LDL-C percentage reduction from baseline. An exploratory analysis assessed the impact of treatment adherence and persistence to incidence of major adverse cardiovascular events (MACEs). A subgroup analysis of patients on FDC of rosuvastatin 10 mg and ezetimibe 10 mg was also conducted.

Methods

A retrospective analysis was performed using the THIN® database from Belgium and France in individuals (aged ≥18 years who received R/E as FDC or FCT between January 01, 2017, and November 30, 2022). Persistence (time from landmark date to discontinuation, with the latter defined as >45 days gap between prescription fills) and adherence (having a proportion of days covered ≥80%) were defined. Subsequent analyses adopted propensity score matching or weighting, followed by Cox and logistic regression models.

Results

A total of 15,643 treatment episodes (FDC: 11,300; FCT: 4,343) were selected. FDC R/E was associated with greater persistence (HR: 0.54, 95% CI: 0.51–0.58) and higher odds of adherence (OR: 3.00, 95% CI: 2.70–3.30) than FCT R/E. Based on the regression analysis results, patients who were persistent to treatment had a 10% higher reduction in LDL-C values from baseline than those non persistent. Similarly, patients who were adherent had 9.6% higher reduction in LDL-C levels from baseline than those not adherent. No significant difference was observed in association between persistence/adherence and MACEs. A consistent trend was also observed in the subgroup analysis.

Conclusions

In conclusion, FDC of R/E use was associated with higher treatment persistence and adherence than FCT of R/E. Patients persistent/adherent to treatment had greater LDL-C reductions than those who discontinued or did not follow treatment schedule. The limited number of MACEs suggests a cautious interpretation of exploratory MACE findings.

Schlagwörter

Stichwörter der Autor:innen

adherenceezetimibefixed-dose combinationfree-combination treatmentmajor adverse cardiovascular eventspersistencerosuvastatinsingle-pill combination

Autor:innen und Institutionen

  • Department of RWE and HEOR Practice, Axtria, Boston, MA, United States.
  • Department of General Medicines Real World Evidence, Sanofi, Bridgewater, NJ, United States.
  • Department of General Medicines and Market Access, Sanofi, Reading, United Kingdom.
  • Global Medical Department of General Medicines, Sanofi, Toronto, ON, Canada.

Zitieren

APA

Samnaliev, M., Khan, I., Potukuchi, P., Lee, K., Garon, G., & Nicholls, C. (2025). Treatment adherence, persistence, and effectiveness of fixed dose combination versus free combination therapy of rosuvastatin–ezetimibe as a lipid-lowering therapy. Frontiers in Cardiovascular Medicine, 12. https://doi.org/10.3389/fcvm.2025.1461416

Vancouver

Samnaliev M, Khan I, Potukuchi P, Lee K, Garon G, Nicholls C. Treatment adherence, persistence, and effectiveness of fixed dose combination versus free combination therapy of rosuvastatin–ezetimibe as a lipid-lowering therapy. Frontiers in Cardiovascular Medicine. 2025;12. doi:10.3389/fcvm.2025.1461416

BibTeX
@article{Samnaliev2025,
  author = {Samnaliev, Mihail and Khan, Irfan and Potukuchi, Praveen and Lee, Kelly and Garon, Genevieve and Nicholls, Charlie},
  title = {Treatment adherence, persistence, and effectiveness of fixed dose combination versus free combination therapy of rosuvastatin–ezetimibe as a lipid-lowering therapy},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2025},
  volume = {12},
  doi = {10.3389/fcvm.2025.1461416}
}
Kostenlos starten →